Open AccessAn 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder
Author(s) -
Shilpa Rele,
Robert Millet,
Sungman Kim,
Jong Hoo Paik,
Seonghwan Kim,
Prakash S. Masand,
Ashwin A. Patkar
Publication year - 2015
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.14m01734
Subject(s) - tolerability , major depressive disorder , serotonin reuptake inhibitor , hamilton anxiety rating scale , randomized controlled trial , medicine , rating scale , psychology , adverse effect , reuptake inhibitor , antidepressant , anxiety , psychiatry , mood , developmental psychology
Vilazodone, a selective and potent 5-HT1A partial agonist and 5-HT reuptake inhibitor, has been approved for treatment of major depressive disorder (MDD) in adults. The primary objective of the study was to compare the efficacy and tolerability of switching to 3 different doses of vilazodone from an equivalent dose range of generic selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) in adult subjects with MDD.